Table 2.

Health Status of patients in the cohort (frequency and percentage, unless otherwise noted)

Characteristic	Total (N=3802)		Primary participants (N=3577)		Revisional participants (N=225)		p value*
Hypertension	2104	55.3	2001	55.9	103	45.8	0.00
Medication:							0.76
No medication	246	11.9	232	11.8	14	13.6
Single medication	897	43.3	851	43.2	46	44.7
Multiple medication	929	44.8	886	45	43	41.7
Diabetes	1323	34.8	1278	35.7	46	20	<.0001
Medication:							0.09
No medication	203	15.4	192	15	11	24.4
Single oral medication	395	29.9	382	29.9	13	28.9
Multiple oral medication	324	24.5	319	25	6	11.1
Insulin (w/or w/o oral meds)	399	30.2	383	30	16	35.6
Congestive heart failure	76	2	69	1.9	7	3.1	0.21
missing, n	2		0		2
Asthma	911	24	853	23.8	58	25.9	0.49
missing, n	1		0		1
Cant walk 200 ft	67	1.8	61	1.7	6	2.7	0.29
missing, n	1		1		0
History of DVT or PE	149	3.9	131	3.7	18	8	0.001
missing, n	1		0		1
Sleep apnea	1860	48.9	1799	50.3	61	27.2	<.0001
missing, n	1		0		1
CPAP	1504	80.9	1467	81.5	37	60.7	<.0001
Supplemental oxygen dependent	74	4	67	3.7	7	11.5	0.00
Ischemic heart disease	153	4	138	3.9	15	6.7	0.03
missing, n	2		0		2
Pulmonary hypertension	45	1.2	40	1.1	5	2.2	0.14
Venous edema w/ulcerations	163	4.6	155	4.7	8	3.8	0.55
missing, n	287		273		14
Number of comorbidities, mean, median	1.80, 2.0		1.82, 2.0		1.43, 1.0		<.0001
Number of comorbidities, n (%)							<.0001
1 or more	3149	82.9	2998	83.8	151	68
2 or more	2101	55.3	2014	56.3	87	39.2
3 or more	1038	27.3	998	27.9	40	18
4 or more	394	10.4	374	10.5	20	9
missing, n	4		1		3
Beta-blocker	687	18.4	642	18.3	45	20.3	0.45
missing, n	64		61		3
Statin/lipid-lowering agent	1008	26.5	969	27.1	39	17.4	0.002
missing, n	1		0		1
Therapeutic anticoagulation	174	4.6	164	4.6	10	4.5	0.93
missing, n	1		0		1
Narcotic	657	17.3	594	16.6	63	28.1	<.0001
missing, n	1		0		1
Anti-depressant	1558	41.7	1450	41.2	108	48.4	0.03
missing, n	63		61		2

^*Chi-square test for categorical variables (with continuity correction for categorical data), Kruskal-Wallis test for continuous variables